Biosurfactants Market Size & Share 2026-2035

Biosurfactants Market Size

The global biosurfactants market was valued at USD 9.6 billion in 2025. The market is expected to grow from USD 10.2 billion in 2026 to USD 14.7 billion in 2035, at a CAGR of 4.1% according to latest report published by Global Market Insights Inc.

The market covers microbial and bio-derived surface-active compounds used in formulations where biodegradability, mildness, wetting, emulsification, or bioactivity can justify a premium over conventional petrochemical surfactants.

Demand is being shaped by a practical substitution question rather than a wholesale replacement of synthetic surfactants. Fermentation-derived glycolipids and lipopeptides can offer biodegradability and functional performance across cleaning, personal care, agriculture, and oilfield applications, but their economics remain constrained by feedstock, fermentation, and purification costs. ^{[1]Frontiers in Bioengineering and Biotechnology, Prospects and challenges regarding biosurfactants in advancing the petroleum industry, 2025, frontiersin.org} Consequently, adoption is strongest where a formulation can monetize improved ingredient positioning, regulatory compliance, or performance at low use rates.

Europe's evolving detergents and surfactants rules provide a defined compliance horizon for formulators. Regulation (EU) 2026/405 will replace the existing detergents framework, with broad applicability beginning on September 23, 2029. ^{[2]European Union, Regulation (EU) 2026/405 of the European Parliament and of the Council on detergents and surfactants, March 2, 2026, eur-lex.europa.eu} At the supply level, Evonik's commercial production from its industrial-scale rhamnolipid facility in Slovakia demonstrates that dedicated microbial-surfactant capacity is progressing beyond laboratory and pilot production.

Regulation (EU) 2026/405 does not require biosurfactants specifically; it requires ultimate aerobic biodegradability for detergent surfactants placed on the EU market and becomes broadly applicable in September 2029. Its significance is that it compresses qualification timelines for compliant alternatives. Suppliers able to provide procurement-ready glycolipids with regulatory documentation and application data can participate earlier in reformulation decisions than suppliers limited to laboratory-scale material. Evonik's Slovakian facility, described by the company as the world's first industrial-scale rhamnolipid biosurfactant plant, illustrates how production scale and application support can convert molecule availability into commercial positioning across personal care, cleaning, coatings, mining, and oil and gas.

Key Drivers

Regulatory reformulation demand

Regulation (EU) 2026/405 establishes updated requirements for detergents and surfactants sold in Europe and creates a dated trigger for reformulation decisions. For biosurfactant suppliers, the opportunity is greatest where biodegradability credentials are paired with stable performance in existing formulations. The regulation does not remove cost pressure, but it increases the commercial cost of delaying qualification of compliant alternatives.

Premium personal care formulations

Rhamnolipids, sophorolipids, and lipopeptides are being incorporated into mild cleansing, skin-care, and specialty cosmetic formulations. Evonik, Solvay, and Kaneka have commercialized biosurfactant offerings for personal care, where low-use-rate performance and ingredient-origin claims can carry more value than in commodity detergents. ^{[3]Solvay S.A., Solvay launches new biosurfactants for carbon-neutral and circular beauty care products, June 2022, solvay.com} This supports the personal care and cosmetics segment's projected 4.36% CAGR.

Oilfield and agricultural functionality

In oil recovery, biosurfactants can reduce interfacial tension, alter wettability, and improve emulsification, although field deployment remains dependent on reservoir conditions and supply economics. Agricultural applications are supported by their ability to improve spray wetting and coverage and, in selected products, provide biological activity alongside adjuvant functionality. ^{[4]MDPI Sustainability, Biosurfactants: Promising Biomolecules for Agricultural Applications, 2024, doi.org} Jeneil Biotech's OMRI-listed Zonix illustrates the commercial value of combining rhamnolipid chemistry with an agricultural-use proposition.

Process development and feedstock flexibility

Waste-stream feedstocks, strain engineering, and improvements in downstream recovery offer avenues to reduce the production burden associated with fermentation-derived materials. These advances are commercially meaningful only when they preserve batch consistency and product purity, especially in cosmetic, food-related, and health-oriented applications.

Key Restraints

Cost and purification burden

Biosurfactant production costs are commonly higher than those of conventional synthetic surfactants because fermentation feedstocks, aeration, foam control, and product recovery add cost at multiple stages. The differential matters most in laundry, industrial cleaning, and other volume applications where surfactant cost is central to formulation economics. Sophorolipid process studies also identify substrate and downstream processing choices as material drivers of unit cost.

Scale-up complexity

Surface activity creates a manufacturing paradox: the product itself can cause foaming and separation challenges during fermentation. Oxygen-transfer limitations, foam management, and recovery methods may reduce yield or increase processing intensity as reactors scale. Industrial investment can address these issues, but it raises capital requirements and favors suppliers with process-development capability and application-specific demand.

Feedstock exposure

Vegetable oils, sugars, and other agricultural inputs expose fermentation producers to commodity-market volatility. Lower-cost residues can improve the cost position, yet variable feedstock composition may complicate process reproducibility and product specification. This trade-off is especially important for end uses requiring controlled purity or predictable sensory and performance attributes.

Technical adoption barriers

Outside established specialty-formulation markets, end users may face reformulation, compatibility testing, and technical-support requirements before changing surfactant systems. These switching costs can delay adoption even when a biosurfactant has an attractive environmental profile.

The restraint is most consequential in price-sensitive laundry, industrial cleaning, and other volume applications, where formulation economics leave limited room for a production premium. By contrast, premium personal care, selected agricultural products, and specialized performance applications can support earlier adoption when mildness, low-dose functionality, or biodegradability has commercial value. Evonik's operating-scale rhamnolipid investment in Slovakia and Stepan's fermentation capabilities in Louisiana indicate that the experience curve is being built through capacity, application learning, and customer qualification rather than feedstock substitution alone. Companies that secure demand in formulation-led segments while improving recovery and batch consistency are better placed to carry that learning into more cost-sensitive applications.

Biosurfactants Market Segment Analysis

By Product Type

Glycolipids are the largest product type, increasing from USD 5.39 billion in 2025 to USD 8.27 billion by 2035 at a 4.14% CAGR. Rhamnolipids and sophorolipids lead commercial activity because they combine surfactant performance with relevance to cleaning and personal care applications. Evonik's industrial rhamnolipid production and Saraya's long-standing sophorolipid commercialization demonstrate two different routes to market: dedicated large-scale fermentation and application-led product development. ^{[5]Saraya Co., Ltd., SOFORO: The world's first commercially successful natural biosurfactant, publication date not available, saraya.world}

Synthetic and semi-synthetic biosurfactants rise from USD 3.09 billion in 2025 to USD 4.78 billion by 2035, at a 4.24% CAGR. This category includes alkyl polyglucosides, methyl ester sulfonates, sorbitan esters, and sucrose esters. Its position between conventional petrochemical surfactants and fermentation-derived specialty materials gives formulators a practical pathway toward renewable-content or biodegradability objectives without adopting the full cost structure of microbial production.

Lipopeptides expand from USD 0.66 billion in 2025 to USD 0.91 billion by 2035. Their specialty profile reflects potent surface activity and potential antimicrobial functionality, but manufacturing economics restrict broad-volume use. Kaneka markets surfactin for cosmetic formulations requiring emulsification at very low concentrations. Phospholipids grow from USD 0.48 billion to USD 0.75 billion over the forecast period, supported by emulsification uses in food, pharmaceutical, and nutraceutical formulations.

By Production Method

Fermentation-based production remains the principal route, growing from USD 5.98 billion in 2025 to USD 9.24 billion by 2035 at a 4.22% CAGR. Its leadership reflects the central role of microbial glycolipids, although its economics depend on productivity, foam management, and downstream recovery. Chemical and enzymatic synthesis rises from USD 3.46 billion to USD 5.26 billion, offering greater structural control for selected high-purity applications.

Hybrid and emerging methods increase from USD 0.18 billion in 2025 to USD 0.22 billion by 2035. Their limited near-term growth reflects a lower level of commercial readiness, but the combination of biological production and enzymatic modification may become more valuable where a customer requires both renewable inputs and tightly controlled molecular characteristics.

By Microbial Source

Bacterial sources increase from USD 4.60 billion in 2025 to USD 6.98 billion by 2035. Rhamnolipid and lipopeptide production has historically relied on bacterial organisms, but safety and regulatory considerations encourage work on non-pathogenic or engineered production hosts. ^{[6]Springer Nature Microbial Cell Factories, Engineering Saccharomyces cerevisiae for the production of sophorolipid biosurfactants, 2026, link.springer.com} Yeast and fungal sources advance from USD 4.45 billion to USD 6.92 billion at a 4.29% CAGR, supported by established sophorolipid fermentation using non-pathogenic yeasts.

Engineered and recombinant strains grow from USD 0.57 billion in 2025 to USD 0.82 billion by 2035. Their value proposition is improved yield, more predictable production, or access to molecular structures not readily produced through conventional fermentation. Such platforms remain dependent on successful scale-up and on regulatory acceptance in each end-use market.

By End-Use Industry

Personal care and cosmetics is the largest end-use industry, rising from USD 3.10 billion in 2025 to USD 4.86 billion by 2035 at a 4.36% CAGR. Mild cleansing, emulsion formation, and skin-oriented positioning support demand for sophorolipids, rhamnolipids, and surfactin. Givaudan's Sopholiance S is positioned for skin-care applications, illustrating the movement from basic surfactancy toward active cosmetic functionality.

Household cleaning grows from USD 2.49 billion in 2025 to USD 3.78 billion by 2035. The segment offers significant volume potential but remains sensitive to delivered cost and cleaning performance. Saraya's SOFORO commercialization in cleaning applications provides a long-running example of sophorolipid deployment where environmental positioning is coupled with use-case validation.

Oil and gas rises from USD 1.05 billion to USD 1.56 billion, while agriculture advances from USD 0.96 billion to USD 1.49 billion. Oilfield demand is concentrated in microbial enhanced oil recovery and related cleaning applications, where reservoir suitability limits uniform adoption. Agricultural demand is linked to adjuvants, crop-protection products, and biological formulations.

Chemical manufacturing increases from USD 0.77 billion to USD 1.16 billion. Pharmaceutical and healthcare grows from USD 0.67 billion to USD 1.00 billion, while food and beverage rises from USD 0.38 billion to USD 0.56 billion. The others category, including bioremediation, textile processing, mining, and specialty extraction applications, expands from USD 0.19 billion to USD 0.31 billion.

Glycolipids retain a structural advantage because sophorolipids and rhamnolipids have the broadest combination of commercial familiarity, scalable fermentation pathways, and application range. Semi-synthetic materials will remain important rather than being displaced: they occupy the cost-performance space that many formulators require while microbial glycolipids continue to build scale.

Biosurfactants Market Regional Analysis

Europe

Europe is the largest regional market, increasing from USD 3.47 billion in 2025 to USD 5.31 billion by 2035 at a 4.14% CAGR. Regulatory change, specialty-chemical infrastructure, and demand from consumer-goods formulators reinforce its position. Regulation (EU) 2026/405 provides a clear regulatory milestone for surfactant suppliers, while Evonik's Slovakian rhamnolipid plant anchors dedicated industrial production capacity in the region.

North America

North America rises from USD 2.81 billion in 2025 to USD 4.42 billion by 2035, representing the highest regional CAGR at 4.39%. The U.S. market grows from USD 2.25 billion to USD 3.53 billion at the same CAGR. Commercial activity spans fermentation-based rhamnolipids, conventional bio-derived surfactants, and agricultural applications. Jeneil Biotech's natural rhamnolipid portfolio and Stepan's biosurfactant investments illustrate the region's mix of dedicated producers and diversified surfactant companies. ^{[7]Stepan Company, Annual Report on Form 10-K for fiscal year ended December 31, 2025, sec.gov}

Asia Pacific

Asia Pacific expands from USD 2.12 billion in 2025 to USD 3.25 billion by 2035 at a 4.15% CAGR. Demand is supported by cleaning, personal care, and agricultural applications, while regional feedstock availability can strengthen the case for local production. Japan remains significant in sophorolipid commercialization through Saraya, whereas China, India, and other large markets offer volume potential tied to consumer-product and agricultural demand.

Latin America

Latin America grows from USD 0.57 billion in 2025 to USD 0.85 billion by 2035 at a 3.85% CAGR. Brazil's agricultural base and availability of sugar- and oil-derived feedstocks make the region strategically relevant for agricultural adjuvants and future fermentation investment. However, local technical infrastructure and supply availability remain uneven.

Middle East & Africa

The Middle East & Africa market rises from USD 0.65 billion in 2025 to USD 0.88 billion by 2035 at a 2.86% CAGR. Oilfield applications offer a defined technical opportunity in mature producing regions, while mining, industrial cleaning, and premium consumer products create more localized demand. Slower growth reflects limited domestic production capacity and continued price competition from established synthetic surfactants.

Asia Pacific has a different growth logic: its opportunity is more volume-oriented and depends on whether regional producers can translate feedstock access and manufacturing capability into reliable application-grade supply. Brazil has longer-term strategic relevance as an agricultural and biofeedstock platform, while the Middle East & Africa will likely remain selective markets centered on oilfield, mining, and imported specialty formulations.

Biosurfactants Market Share & Competitive Landscape

Competition is differentiated by molecule class, production route, purity, regulatory documentation, and application support. Large specialty-chemical companies compete through scale and established customer access, while focused producers emphasize fermentation know-how, high-purity materials, or specific end uses.

Allied Carbon Solutions Co., Ltd. specializes in sophorolipid products made through yeast fermentation. BASF acquired an equity stake in the company and entered a cooperation arrangement for biosurfactant development, strengthening the commercial pathway for sophorolipids in personal and home care applications. ^{[8]BASF SE, BASF strengthens its position in bio-surfactants for personal care, March 2021, basf.com}

Evonik Industries AG operates its industrial-scale rhamnolipid facility in Slovenská Ľupča, Slovakia. Its biosurfactant portfolio addresses personal care, cleaning, coatings, and related specialty applications.

Givaudan participates through its Active Beauty business, including Sopholiance S for cosmetic applications. Its positioning centers on functional cosmetic performance alongside natural-origin formulation credentials.

GlycoSurf LLC develops high-purity glycolipid surfactants through synthetic chemistry. Its approach is relevant where molecular consistency and purity are central to performance or regulatory requirements.

Jeneil Biotech, Inc. produces natural rhamnolipid biosurfactants for agricultural, cleaning, remediation, and related uses. The company received a U.S. Environmental Protection Agency Green Chemistry Award for its commercial biosurfactant work.

Kaneka Corporation supplies KANEKA Surfactin, a lipopeptide biosurfactant used in cosmetic and emulsification applications at low concentrations.

Saraya Co., Ltd. commercialized SOFORO sophorolipid technology for cleaning and hygiene uses and continues to use biosurfactants across consumer and professional cleaning applications.

Solvay S.A. launched Mirasoft sophorolipid-based biosurfactants for beauty care formulations, positioning them as bio-based and readily biodegradable alternatives for selected personal care products.

Stepan Company expanded its biosurfactant capabilities through the NatSurFact business and fermentation assets in Louisiana. Its broader surfactant portfolio gives it access to high-volume formulation channels as rhamnolipid capacity develops.

Synthezyme LLC develops modified sophorolipids using engineered yeast and chemical modification. Its collaboration model targets enhanced-function surfactants for specialty applications, including antimicrobial formulations.

Recent Industry Developments

Evonik's World-First Industrial-Scale Rhamnolipid Plant Launches Commercial Production (January 2024)

In January 2024, Evonik Industries manufactured the first commercial product from its industrial-scale rhamnolipid biosurfactant facility at Evonik Fermas in Slovenská Ľupča, Slovakia, the only plant of its kind globally at industrial scale. The facility uses an IP-protected biotechnological fermentation process with European corn sugar as its primary renewable feedstock. By Q4 2024, Evonik's biosurfactants and biofunctional ingredients portfolio had grown 21% in the period, with the company expanding rhamnolipid applications from personal care and cleaning into paints and coatings, mining, and oil and gas.

EU Adopts Regulation (EU) 2026/405 Mandating Surfactant Biodegradability (March 2026)

The European Union published Regulation (EU) 2026/405 on March 2, 2026, replacing Regulation (EC) 648/2004 with full applicability from September 23, 2029. The regulation mandates ultimate aerobic biodegradability for all detergent surfactants placed on the EU market and introduces Digital Product Passports for detergent and surfactant products. It creates a binding compliance timeline that directly increases demand for biodegradable biosurfactant alternatives across Europe's detergent, household cleaning, and personal care industries.

BASF Acquires Equity Stake in Allied Carbon Solutions, Enters Biosurfactant Cooperation (March 2021)

BASF announced in March 2021 that it had acquired an equity stake in Allied Carbon Solutions Co., Ltd., making BASF the company's single largest shareholder, and entered an exclusive technology cooperation and commercial agreement for sophorolipid product development. The partnership is directed at expanding sophorolipid supply for personal care and home care applications and represents one of the largest corporate commitments to sophorolipid commercialization in the global market.

Advances in CRISPR-Mediated Biosurfactant Strain Engineering Published (2025–2026)

Peer-reviewed research published in 2025 and 2026 confirmed the viability of CRISPR-Cas9 for biosurfactant yield enhancement. CRISPR-Cas9 disruption of regulatory genes in *Pseudomonas aeruginosa* IGLPR01 enhanced rhamnolipid production with improved hydrocarbon emulsification. Metabolic engineering of *B. subtilis* via CRISPR-Cas9 achieved surfactin yields up to 3.5 times above wild-type strains. Metabolic engineering of *S. cerevisiae* for sophorolipid production through heterologous pathway expression demonstrated host-switching away from organisms with biosafety limitations. These advances are accelerating the translation from laboratory to pilot-scale commercial production.

Allied Carbon Solutions Expands Sophorolipid into Animal Nutrition (2024)

Allied Carbon Solutions' ACS-Sophor® sophorolipid expanded into livestock feed emulsification applications in 2024, with large-scale field trials at pig farming and egg-laying facilities in Japan demonstrating improved intestinal fat and nutrient absorption efficiency. The application was co-developed with Rock Chemical Products for distribution in the Japanese agricultural market and represents a commercial use case for sophorolipids distinct from cleaning, personal care, and agricultural chemical markets.